Enzo Life Sciences announces a new primary antibody validated for IHC, our p16INK4A monoclonal antibody. A cyclin-dependent kinase inhibitor, p16 plays an important regulatory role in the cell cycle. It naturally decelerates cellular differentiation and therefore acts as a tumor suppressor, making it an important marker in many cancers. For example, p16 has been indicated in carcinomas of the lungs, colon, liver, cervix, and many others. Enzo’s p16INK4A antibody is designed to deliver staining quality when paired with Enzo’s POLYVIEW PLUS IHC Detection Reagents.